Galapagos doses first healthy volunteer with CF combo GLPG2222 and GLPG2451
Mechelen, Belgium; 23 February 2017 - Galapagos NV (Euronext & NASDAQ: GLPG) announces dosing of the first healthy volunteer with a combination of novel corrector GLPG2222 and novel potentiator GLPG2451 for cystic fibrosis in a Phase 1 study. After …